Switch to:
More From Other Websites
Regeneron, Sanofi Get Approval For Eczema Drug Priced At $37,000 Mar 28 2017
FDA approves Regeneron, Sanofi $37,000 per year eczema drug Mar 28 2017
Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval Mar 28 2017
[$$] FDA Approves Regeneron and Sanofi's Dupixent for Eczema Mar 28 2017
FDA approves Sanofi Genzyme drug amid questions over patent, cost Mar 28 2017
Regeneron, Sanofi Score Eczema Drug Approval Mar 28 2017
Regeneron, Sanofi announce FDA approval of atopic dermatitis treatment Mar 28 2017
11:41 am Sanofi and Regeneron Pharmaceuticals (REGN) announce... Mar 28 2017
Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic... Mar 28 2017
Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic... Mar 28 2017
FDA approves Regeneron, Sanofi eczema drug Mar 28 2017
VIVUS to Regain Commercial Rights for Stendra from Sanofi Mar 28 2017
GlaxoSmithKline’s Valuation Compared to Its Peers Mar 28 2017
Pfizer Rheumatoid Arthritis Drug Approved in EU Mar 27 2017
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi Mar 27 2017
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi Mar 27 2017
Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin Mar 25 2017
Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low? Mar 24 2017
Big Decision Week for Roche, GSK, Sanofi, Mylan Mar 24 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK